Genetic and functional heterogeneity of the hepatitis C virus p7 ion channel during natural chronic infection  by Li, Hui et al.
Virology 423 (2012) 30–37
Contents lists available at SciVerse ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r .com/ locate /yv i roGenetic and functional heterogeneity of the hepatitis C virus p7 ion channel during
natural chronic infection
Hui Li a, Elizabeth Atkins b, Joseph Bruckner a, Susan McArdle a, Wan Chong Qiu a, Lisa V. Thomassen c,
John Scott d, Margaret C. Shuhart d, Stephen Livingston e, Lisa Townshend-Bulson e, Brian J. McMahon e,
Mark Harris b, Stephen Grifﬁn b,f, David R. Gretch a,⁎
a Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
b Institute of Molecular and Cellular Biology, University of Leeds, Leeds, West Yorkshire, UK
c Department of Pathology, University of Washington, Seattle, WA, USA
d Department of Medicine, University of Washington, Seattle, WA, USA
e Liver Disease & Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA
f Leeds Institute of Molecular Medicine, Faculty of Medicine & Health, University of Leeds, St James's University Hospital, Leeds, West Yorkshire, UK⁎ Corresponding author at: Harborview Medical Cen
Ninth Ave, Seattle, WA 98104, USA. Fax: +1 206 897 5
E-mail address: gretch@uw.edu (D.R. Gretch).
0042-6822/$ – see front matter © 2011 Elsevier Inc. All
doi:10.1016/j.virol.2011.11.011a b s t r a c ta r t i c l e i n f oArticle history:
Received 13 July 2011
Returned to author for revision 1 August 2011
Accepted 11 November 2011
Available online 14 December 2011
Keywords:
Hepatitis C virus
p7 ion channel
Genetic heterogeneity
Functional heterogeneity
Hyperactive channel activity
pH-activated channel activityThe present study describes natural genetic heterogeneity of hepatitis C virus (HCV) p7 protein, the ion channel
that plays a critical role in assembly and release of HCV,within 299 variants isolated from serum specimens of 27
chronically infected patients, 12 of whomwith human immunodeﬁciency virus (HIV) co-infection. Liver ﬁbrosis
stage was inversely correlated with p7 synonymous substitutions (dS) (p=0.033), and indices of p7 genetic
diversity were signiﬁcantly higher in HIV-negative subjects compared to HIV-positive subjects (dS, p=0.005;
non-synonymous substitutions (dN), p=0.002; dN/dS ratio, p=0.024; amino acid distances, p=0.007). Six
p7 genes with naturally occurring unique amino acid variations were selected for in vitro study. The variants
demonstrated diversiﬁed functional heterogeneity in vitro, with one variant from a subject with severe liver
disease displaying hyperactive ion channel function, as well as other variants presenting altered pH-activated
channel gating activities.
© 2011 Elsevier Inc. All rights reserved.Introduction
Chronic infection with hepatitis C virus (HCV) represents a major
and growing global health concern, and is now the leading cause of
liver cirrhosis, hepatocellular carcinoma, and death due to liver disease
in the United States and other developed nations. Although 20–30% of
HCV-infected patients spontaneously clear the virus, the majority of
infections progress to the chronic phase, characterized by continuous,
high level viremia, and a high degree of viral genetic heterogeneity.
The long term clinical course of chronic HCV infection is highly variable:
only about 20% of such cases develop into progressive liver disease,
typically over a 2–3 decade period of infection (McMahon et al., 2010;
Seeff et al., 2000). The leading pathogenesis model assumes that liver
damage is largely mediated by cytotoxic immune responses, and other
adverse consequences of chronic inﬂammation, including generation
of toxic free radicals, such as reactive oxygen species (Mengshol et al.,
2007). However, several lines of evidence suggest that viral factors
may also play a role in hepatitis C disease, the most striking beingter NJB-345, Box 359743, 325
203.
rights reserved.selection of cytopathic HCV infectious clones in vitro (Mishima et al.,
2010), and identiﬁcation of HCV-associated cytopathic effects in im-
mune deﬁcient, chimeric mice in vivo (Joyce et al., 2009). During
human infection, studies have revealed highly signiﬁcant differences
in HCV genome evolution between mild and severe disease subjects,
with viral sequence homogenization, and accumulation of synonymous
mutations (dS) within HCV genomesmore extensive during severe dis-
ease (Li et al., 2008; Sullivan et al., 2007). Our recent study of 54 near
full-length HCV genomes circulating in chronically infected humans
over time revealed signiﬁcant ﬁxation of amino acid sequences during
severe disease in four HCV genes: p7, NS2, NS3 and NS5B (Li et al.,
2011). Whereas high genetic heterogeneity of HCV likely contributes
to viral persistence via immune escapemechanisms, the functional con-
sequences of HCV genome ﬁxation during natural, in vivo infection of
humans have not been previously characterized.
The genome of HCV is a 9.6 kb positive-sense single strand RNA
that encodes 5′ and 3′ untranslated regions (UTRs), plus a single poly-
protein of approximately 3011 amino acids in length. Following cap-
independent translation, the polyprotein is cleaved by both host and
viral proteases to yield 10 functional mature proteins, including 3
putative structural proteins (core, envelope 1 (E1), and envelope 2
(E2)), an ion channel protein (p7), and 6 non-structural proteins
31H. Li et al. / Virology 423 (2012) 30–37(NS2, NS3, NS4A, NS4B, NS5A, and NS5B). The ion channel protein p7
is a newmember of a family of viroporins (Grifﬁn et al., 2003; Pavlovic
et al., 2003; Premkumar et al., 2004), a class of small viral hydrophobic
proteins that oligomerize to form ion channels capable of modifying
cell membrane permeability (Gonzalez and Carrasco, 2003). The 63-
amino acid p7 protein forms a hairpin structure, with two trans-
membrane alpha helices connected by a short loop containing two
highly conserved basic residues (Cook and Opella, 2011; Grifﬁn et
al., 2004; Montserret et al., 2010). Electron microscopy studies ob-
served a hexameric channel, with a pore diameter of 3–8 nm in artiﬁ-
cial membrane (Grifﬁn et al., 2003; Luik et al., 2009), while a
heptameric structure was also reported (Clarke et al., 2006). Although
p7 is evidently not necessary for viral replication in vitro, the presence
of p7 is essential for productive HCV infection in vivo (Sakai et al.,
2003), as well as assembly and release of infectious virions in vitro
(Jones et al., 2007; Steinmann et al., 2007). Recently, we showed
that p7 achieves this by virtue of possessing proton channel activity
in mammalian cells, which protects nascent, immature virions from
acidic environments during secretion (Wozniak et al., 2010).
The aim of the present study was to further characterize the natu-
ral variability of the HCV p7 proton channel in chronically infected
humans, in the absence or presence of HIV coinfection, and to deter-
mine if p7 genetics differs in HCV genotype 1 infected research sub-
jects with mild compared to severe hepatitis C disease. The study
also reports initial characterization of natural functional activities of
p7 variants isolated from a subset of research subjects with mild
and severe disease. Selected variants were expressed in vitro, and
both channel activity, as well as activation by acidic pH, were
assessed using a liposome-based ﬂuorescent dye release system
(StGelais et al., 2007).
Results
Patient characteristics
The demographic and clinical characteristics of the 27 patients
recruited from our cross sectional study at the Harborview Medical
Center site, Seattle, Washington, are listed in Table 1, according to
HIV infection status. All 27 patients were infected with HCV genotype
1a. The HIV negative and HIV positive groups were similar in age
(mean 44.3 vs. 44.0 years, respectively; p=0.93) as well as duration
of HCV infection (mean 21.6 years vs. 17.0 years, respectively;
p=0.25). Furthermore, there were no signiﬁcant differences in either
mean HCV viral load, mean AST value in serum, or mean ALT value in
serum, between HIV positive and negative groups (Table 1). The sta-
tus of liver disease was evaluated by liver biopsy at the time of patientTable 1
Demographical and clinical characteristics of the 27 patients recruited at Seattle. Data
are shown inmean and standard deviation. The groups were compared using the Fisher's
exact test for the gender and race or the Student t test for the other characteristics.
Characteristics HIV negative
(n=15)
HIV positive
(n=12)
p value
Age 44±6 44±9 0.93
Gender 0.09
Male 9 11
Female 6 1
Race 0.38
Caucasian 9 8
African American 1 3
Hispanic 3 0
Native American 2 1
HCV duration (year) 22±9 17±10 0.25
AST (U/L) 59±60 121±150 0.16
ALT (U/L) 76±64 136±135 0.18
HCV RNA (log10IU/ml) 6.5±0.6 6.4±1.3 0.87
Inﬂammation grade (0–4) 1.5±0.7 1.9±0.8 0.21
Fibrosis stage (0–4) 1.9±0.9 2.1±1.0 0.56recruitment, within 30 days of serum procurement for p7 sequencing
studies; no difference was found between the HIV negative and HIV
positive groups with respect to inﬂammation (mean grade 1.5 vs.
1.9, respectively; p=0.21) or ﬁbrosis stages (mean stage 1.9 vs. 2.1,
respectively; p=0.56).
Genetic diversity of the HCV p7 gene according to HIV status and disease
severity
A total of 299 p7 variants were sequenced from the serum sam-
ples of the 27 patients recruited in Seattle. The genetic diversity of
p7 variants was compared according to HIV infection status, and
data are summarized in Fig. 1 and Table 2. Synonymous substitutions
(dS) were more frequent than non-synonymous substitutions (dN)
in p7 genes isolated from both groups, regardless of the HIV infection
status (dS=0.0349 versus dN=0.0061 for HIV negative patients,
pb0.01; dS=0.0144 versus dN=0.0011 for HIV positive patients,
pb0.01). Both synonymous and non-synonymous substitutions were
signiﬁcantly higher in HIV negative versus HIV positive subjects
(p=0.005 and p=0.002 for dS and dN, respectively). Similarly, the
HIV negative patients showed signiﬁcantly greater genetic diversity at
both nucleotide (p=0.003) and amino acid (p=0.007) levels. The
dN/dS ratio, generally considered as an indicator of host immune pres-
sure, was signiﬁcantly higher in HIV negative subjects compared to HIV
positive subjects (p=0.024).Fig. 1. Nucleotide substitutions of p7 from HCV monoinfected and HIV/HCV coinfected
subjects. The Mann–Whitney U test was used to compare the median of the two
groups. A) Synonymous nucleotide substitution (dS). B) Non-synonymous nucleotide
substitution (dN). C) dN/dS ratio.
Table 2
Comparison of the median genetic parameters between the HCV monoinfected patients
and HIV/HCV coinfected patients. dS, the synonymousmutations, indicates the proportion
of observed synonymous mutations over the number of potential synonymousmutations
of the pairwise comparison. dN, the non-synonymous mutations, indicates the proportion
of observed non-synonymous mutations over the number of potential non-synonymous
mutations of the pairwise comparison. p values were calculated with the Mann–Whitney
test.
dS dN dN/dS Nucleotide
distance
Amino acid
distance
HIV neg 0.0349 0.0061 0.1727 0.0135 0.0154
HIV pos 0.0144 0.0011 0.0870 0.0070 0.0070
p value 0.005 0.002 0.024 0.003 0.007
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gene synonymous substitutions was signiﬁcantly higher among subjects
with mild disease (ﬁbrosis scores of 0–1) compared to subjects with
severe disease (ﬁbrosis 3–4) (p=0.016). In concordance, synonymous
substitutions were negatively correlated with ﬁbrosis stage at statistical
signiﬁcance (r=−0.412, p=0.033) (Fig. 2A). The lowest medians of
non-synonymous substitution, nucleotide distance, and amino acid dis-
tance, were found in the patients with severe disease, although the dis-
tribution of these parameters was not statistically signiﬁcant (Figs. 2B,
C and D). The lack of statistical signiﬁcance for the latter comparisons
may be due to under sampling bias.
p7 amino acid variation
The amino acid residues of the 299 sequenced variants from 27 sub-
jects were highly conserved, with an average of 93% sequences showing
identical amino acid per site. 8 residue positions were highlighted with
amino acid variations in more than 20% of the total sequences, including
position 7 (35%V, 33% L, 16% I, and 15% T), position 16 (77% T and 23%A),
position 20 (63% V, 32% A, and 5% I), position 35 (61% R, 38% K, b1% G,
and b1% T), position 37 (77% V, 19% A, and 4% M), position 40 (72% A,
19%V, 5% M, and 4% T), position 41 (52% A and 48% V), and position 44
(47% F, 29% L, 15% V, 8% I, and 1% C).Fig. 2. Inverse correlation between genetic parameters of p7 diversity and liver ﬁbrosis stag
disease). The correlation coefﬁcients, and p values, were calculated using Spearman corr
synonymous nucleotide substitution (dN) and ﬁbrosis stage. C) p7 nucleotide distance andIn Fig. 3, the frequency ofmost common amino acids, per site, is plot-
ted according to HIV infection status (Fig. 3A), and liver disease severity
(Fig. 3B), over the full-length p7 frame. Overall, the amino acid identity
per site was similar between the HIV negative and HIV positive groups
(92.8% vs. 93.1%), with position 20 showing the greatest difference
(73% V vs. 51% V for HIV negative and positive groups, respectively).
When comparing among disease groups, greater than 20% difference
in amino acid identity was found on 6 residue positions between the
mild (ﬁbrosis 0–1) and severe (ﬁbrosis 3–4) disease groups, including
positions 6 (60% V vs. 100% V), 7 (27% I vs. 52% L), 16 (89% T vs. 63% T),
17 (75% H vs. 100% H) and 20 (80% V vs. 52% A).Cloning and expression of naturally occurring p7 variants
Genetic data revealed interesting, potentially signiﬁcant non-
synonymous changes in primary amino acid sequences of several p7
genes isolated from both mild and severe disease individual cases.
Therefore, in vitro functional studies were performed. Naturally oc-
curring HCV p7 gene variants were cloned from serum specimens of
3 subjects from the Harborview cohort study (M1, M2 and S1) and
2 additional subjects enrolled in the Alaska Native cohort study
(McMahon et al., 2004) (S2 and S3). From these 5 subjects, six unique
p7 variants were selected for in vitro testing of ion channel activities,
with H77 (genotype 1a) and J4 (genotype 1b) p7 clones serving as
prototype controls (Fig. 4 and Table 3). Variant M1_4, with mutations
of S21P, P38S, and A40T, was obtained from an HIV-negative Seattle
patient with mild disease (ﬁbrosis stage 1). Variant M2_1, with a mu-
tation of H17R, was obtained from an HIV-positive Seattle patient
with mild disease (ﬁbrosis stage 0). Variant S1_1, with a mutation
of Y31H, was obtained from an HIV-negative Seattle patient with se-
vere disease (ﬁbrosis stage 3). Variant S2_167, with mutations of
H17N and F44C, was obtained from an HIV-negative patient with se-
vere disease (ﬁbrosis stage 3). Variants S3_175 and S3_180 were
obtained from another HIV-negative patient with severe disease (ﬁ-
brosis stage 3). Both variants had T16A, while the latter one had
R35G and V41T.e in research subjects (0–1 for mild disease, 2 for moderate disease, and 3–4 for severe
elation test. A) Synonymous nucleotide substitution (dS) and ﬁbrosis stage. B) Non-
ﬁbrosis stage. D) p7 amino acid distance and ﬁbrosis stage.
Fig. 3. Amino acid variation of the p7 protein in the patients from the coinfected cohort. Panel A, percentage of the most frequent amino acid residues in HIV negative and HIV pos-
itive patients. Panel B, percentage of the most frequent amino acid residues in patients with mild (ﬁbrosis stages 0–1), moderate (ﬁbrosis stage 2) and severe (ﬁbrosis stages 3–4)
disease. Panel C, alignment of the consensus sequences from each group.
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We recently showed that p7 acts as a proton channel in cellular
membrane compartments, inducing vesicle alkalinization to protect
intracellular virions from acidic pH at an as-yet undeﬁned stage of
virion release (Wozniak et al., 2010). Accordingly, we have also
shown that the genotype 1b J4 p7 protein displays increased activity
at reduced pH (StGelais et al., 2007), consistent with a gating mecha-
nismmediated by ionization of lumenal amino acid residues, including
His17. To investigate whether amino acid variation, particularly within
lumenal residues, observed in patient sequences could lead to a direct
effect on p7 ion channel function, we expressed selected proteins
in vitro and analyzed activity in a liposome-based ﬂuorescent dye
release assay (StGelais et al., 2007). All proteins were efﬁciently
expressed as visualized by Coomassie-stained SDS PAGE and different
sequences caused variation in electrophoretic mobility, as seen previ-
ously (Grifﬁn et al., 2005, 2008) (Fig. 5). The liposome-based dye
release assay revealed one variant, S2_167 from a patient with severe
disease, with markedly enhanced channel activity compared with H77Fig. 4. Sequence alignment of the tested variants. J4 p7 is a much-studied genotype 1b sequ
patient isolate sequences compared with H77 are shown. Positions 17, 31 and 35 are highland/or J4, indicative of a hyper-activated channel (Fig. 6). This protein
contained a H17N non-synonymous variation in the lumen, which is
common to many genotype 2 HCV isolates, as well as F44C within the
C-terminal helix.
We next tested channel activity under conditions where the pH of
the external milieu (pHext) was altered relative to the liposome inte-
rior (pH 7.0). We have previously noted a marked increase in activity
for J4 p7 when pHext was reduced below pH 7.0 (StGelais et al., 2007).
As seen previously, J4 channel activity was markedly increased at
acidic pH (Fig. 7A), whereas the prototype genotype 1a H77 protein
displayed a different pattern of activation that was not enhanced by
reduced pH; indeed, activity was reduced at near-neutral values
(pH 6.7) compared with either mildly acidic (pH 6.2) or alkaline
(pH 7.4) conditions. The majority of the patient variants tested
(M2-1, S2-167, S3_175 and S3_180) behaved essentially as H77 in
the pH activation assay with slightly reduced activity at pH 6.7 com-
pared with 7.4 and 6.2 (Figs. 7C and D). Interestingly, two patient
variants behaved more akin to the genotype 1b J4 p7 compared to
H77, whereby channel activity was markedly increased by reducingence; H77 is the prototype genotype 1a sequence. Amino acid changes present in the
ighted to show mutations of interest.
Table 3
Major amino acid changes of the six tested p7 variants compared to J4 and H77.
Variant Amino acid
change
Host characteristics
Fibrosis stage HIV status
M1_4 S21P, P38S, A40T 1 Negative
M2_1 H17R 0 Positive
S1_1 Y31H 3 Negative
S2_167 H17N, F44C 3 Negative
S3_175 T16A 3 Negative
S3_180 T16A, R35G, V41T 3 Negative
Fig. 6. Real-time dye release assay after addition of p7 proteins. A) 5 μg of each of the
proteins in methanol was added to 50 μM of liposomes containing CF, and dye release
measured every 30 s over a period of 30 min. Controls were liposomes alone, liposomes
with methanol, liposomes with the pore-forming peptide melittin and liposomes with
0.5% triton (melittin and triton controls omitted for scale). Each sample was carried out
in duplicate and the mean plotted for each sample. B) Initial reaction rates taken from
the above real-time dye release assay and shown as ﬂuorescent units released per sec-
ond (FU/s). Gradients for the ﬁrst 300 s were taken by plotting the regression line for
each sample, then calculating the mean and standard deviation for each protein
(n=2).
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(S1-1) cases. M1-4 contained non-synonymous S21P and A40T
changes, of which S21P would be predicted to affect the channel
lumen. Interestingly, S1-1 contained a Y31H change which is also
present within the channel lumen and variation at this position has
previously been shown to inﬂuence virion production in a genotype
2a background (Brohm et al., 2009).
Discussion
Recently, the evolution of HCV genetic diversities has been studied
in multiple cohorts with longitudinal clinical follow-ups. It has been
shown that during natural HCV infection (Li et al., 2008; Sullivan et
al., 2007), during HIV coinfection (Shuhart et al., 2006), and in the
setting of immune suppression after liver transplantation (Li et al.,
2010; Sullivan et al., 1998), genetic homogenization of HCV quasispe-
cies is signiﬁcantly associated with progression of severe hepatitis C
disease. This distinctive virological phenomenon is also observed
in the near full-length HCV open reading frame, with viral protein
sequences signiﬁcantly conserved over time in patients with severe
disease (Li et al., 2011). For the present study, the sequence variabil-
ity of the ion channel protein p7 was analyzed in a sub-cohort of 27
patients with chronic HCV infection, 12 of whom were coinfected
with HIV. P7 genetic diversity, as indicated by synonymous substitu-
tions, non-synonymous substitutions, dN/dS ratio, and amino acid
distances, was signiﬁcantly higher in HIV negative patients compared
to HIV positive ones. The severity of liver disease was evaluated for all
the patients by liver biopsies. The liver ﬁbrosis stage was inversely
correlated with synonymous substitutions, which is in consistence
with previous studies that genetic homogenization coincidently
occurs with advanced liver disease.
The p7 protein, as a member of the viroporin family, shares se-
quence and functional similarity to the M2 channel protein ofFig. 5. In vitro expression of six p7 variants. All 6 proteins were expressed as GST fu-
sions with a FLAG tag on the N-terminus of the p7 sequence. The GST was then cleaved
off and the proteins were puriﬁed by HPLC. 5 μg of each protein was loaded and stained
with Coomassie Blue in the following order: 1) H77 p7; 2) M1_4 p7; 3) M2_1 p7; 4)
S2_167 p7; 5) S1_1 p7; 6) S3_175 p7; 7) S3_180 p7.inﬂuenza A virus. M2 channel structure has been widely studied in
strains of inﬂuenza A virus with mutational analysis of the channel
gating mechanism. His37 of M2 has been proposed as a pH sensor
that causes a conformational shift in the gating residue Trp41 and
leads to channel opening on protonation (Tang et al., 2002). Similarly,
a counterpart has been identiﬁed in p7 of HCV by sequence and struc-
tural analysis, including His17 present in the lumen of the channel
(Chew et al., 2009), and Tyr31 at the end of trans-membrane domain
1 (Brohm et al., 2009), likely as the gating residues. Although muta-
genesis studies with H17A in the genotype 1b J4 strain showed highly
reduced activity in a liposome-based ﬂuorescent dye-release assay
(StGelais et al., 2009), the same mutation showed no inhibition of
channel activity in the genotype 1a H77 strain (Chew et al., 2009),
and little effect on the production of infectious virions in the
genotype 2a JFH1 strain (Brohm et al., 2009). The basic residues Arg
33 and Arg 35 in the highly conserved loop region between the two
trans-membrane regions have also been shown essential to the p7
channel activity. Mutations R33A R35A in the basic loop region
resulted in no production of infectious virions in the full length JFH1
system, while the less geometrically extreme mutant R33Q R35Q
showed a substantial reduction of infectious virions (Steinmann
et al., 2007).
In the present study, a large variation of p7 sequences were
observed among different patient isolates, and six variants were
selected for in vitro liposome dye-release assay to analyze channel
activity. As the prototype control, H77 p7 showed relatively stable
channel activity to various pH, while J4 p7 showed signiﬁcantly in-
creased activity when pH decreased from 7.4 to 6.2. Given that the
H17A mutation does not inhibit H77 p7 channel activity in black
lipid membranes (Chew et al., 2009), His17 in H77 p7 may not be
as important in channel functions as the same histidine of J4 p7. In
contrast to the J4 p7, in which the protonated His17 potentially
Fig. 7. pH response assay of the p7 proteins. For all proteins, a control was included of
J4 p7 at pH 7.4 to which all other results were normalized. Liposomes were pelleted
and resuspended in assay buffer at pH 7.4, 6.7 and 6.2 and incubated with p7 protein.
The remaining liposomes were removed by centrifugation, and the ﬂuorescence of the
supernatants was tested. Background controls of dye release with methanol alone were
subtracted from the p7 results. Each sample was tested in duplicate, here showing the
mean with error bars representing the standard deviation. Results are shown as:
A) wild-type p7 from the genotype 1b J4 and genotype 1a H77. B) pH responsive
patient isolates M1_4 and S1_1. C) H17 mutants that were not pH responsive, M2_1
and S2_167. D) Patient isolates that had H17 but were not pH responsive, S3_175
and S3_180.
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channel activity is likely to remain at a relatively high level, and the
slightly decreased activity at near neutral pH is likely due to bi-
directional proton gradients. Such channel activity was still observed
from the proton-regulated J4 channels at pH 7.4, and from H77 chan-
nels at neutral pH, which may be due to the CF concentration gradient
between the liposome interior, and the external milieu forces.
The naturally occurring p7 variants we selected for study showed
a wide variation in channel activity. The most active variant, S2_167,
has a H17N mutation at the inner surface of p7 lumen. The side group
of asparagine is polar rather than charged, and smaller than both
arginine and histidine. It is possible that this mutation can create a
constitutively open channel that is unresponsive to pH. Interestingly,
the J6 p7 sequence has N17, and this confers greater virion produc-
tion when introduced into other genotype chimeras, potentially due
to increased channel activity (Steinmann et al., 2007). In addition,
the F44C mutation of S2_167 at the second trans-membrane domain
may disrupt hydrophobic interactions that make the channel com-
plex stable, resulting in a more “open” structure. The S3_180 variant,
with mutation of one of the two highly conserved basic loop residues,
R35G, still appears to be a functional channel in the in vitro dye-
release assay. This observation argues against the role of these basic
loop residues in channel activity, although a previous study reportedthat the K33A/R35A mutant exhibited drastic decrease in the assem-
bly and release of infectious intracellular virions (Jones et al., 2007).
Both S3_175 and S3_180 variants have the T16A mutation and
showed broadly similar activity and pH response compared to the
H77 prototype. The residue at position 16 in J4 p7 is also alanine, so
it is possible that this mutation is not signiﬁcant in channel activity.
Two variants, M1_4 and S1_1, showed increased channel activity at
acidic pH. The pH response of M1_4 is possible due to the increased
hydrophobicity within the lumen as a result of S21P. Amore hydropho-
bic lumen may require more energy or a shift in protein conformation
(such as seen in J4) for ions to be transported across. Introducing a P
could also cause a bend in the helix that could alter the structure signif-
icantly. The mutation of Y31H, in the variant S1_1, potentially serves as
a pH-sensor gating residue at the cytosolic end of the channel that could
make it responsive to pH. Interestingly, the JFH-1 strain, which shows
more pH responsiveness than J4, also contains histidine at this position,
although mutation of H31 showed no signiﬁcant effect on virion pro-
duction (Steinmann et al., 2007). The histidine mutant M2_1 showed
no pH responses, although the channel activity remained constitutively
high in the tested pH range. This variant contains a unique H17R substi-
tution, in which arginine, with amuch higher pKa (12.1), replaces histi-
dine (pKa=6.04). Since arginine is only deprotonated at much higher
pH, the channel gating effect probably occurs at a higher pH range.
Further experimentation is needed to elucidate if such pH gatingmech-
anisms exist.
It remains hotly debated whether genetic heterogeneity is naturally
associatedwith functional heterogeneity in highlymutated RNA viruses
such as HCV. A recent study on HCV NS3-NS4A proteins demonstrated
that the protease activities of genotype 4a, 5a, and 6a isolateswere sim-
ilar to those of genotype 1b and 2a references, while a genotype 2a
variant demonstrated a signiﬁcantly higher helicase activity compared
to other HCV genotypes (Massariol et al., 2010). Meanwhile, tumor-
derived HCV core variants have been shown to signiﬁcantly inhibit
the tumor growth factor-beta (TGF-beta) pathway, in contrast to mod-
erate or no effects observed with non-tumor variants or reference
clones (Pavio et al., 2005). In our study, we characterized the channel
activity of six p7 variants isolated from serum specimens of HCV-
infected patients, and our results indicated that p7 variants with genetic
variation exhibit functional variability at an extended range. As a pre-
liminary study, the number of variants is still small to draw correlation
between p7 activity and disease severity. For example, the variantM2_1
from a patient with mild disease showed constitutively high activity,
with no change in response to pH,while the variant S1_1 from a patient
with severe disease showed relatively low activity, with an increase in
response to reduced pH. However, viral genetic homogenization during
severe disease highlights the possibility of variant outgrowth in a man-
ner related to the pathogenesis of hepatitis C disease.
In summary, the present study documents genetic and functional
heterogeneity of the HCV p7 protein in nature, and sets the stage for
understanding whether or not naturally occurring heterogeneity in
HCV translates into differences in efﬁciency of virogenesis, or viral dis-
ease potential. Further experiments will be performed to characterize
the channel activity of the isolated p7 variants under a wide range of
pH conditions. Since liposomes are unable to tolerate pH lower than 6,
p7 proteins will be expressed in Xenopus oocytes followed by patch
clamping to increase the pH range that can be studied. The patient var-
iants will be further investigated in the chimeric H77/JFH1 virus devel-
oped by S. Lemon et al. (Yi et al., 2007) for details on the effects of these
mutations in viral particle release and drug susceptibility.
Materials and methods
Study subjects and specimens
Twenty-seven subjectswith chronic HCV genotype 1a infectionwere
recruited at the Harborview Medical Center at Seattle, WA. All patients
36 H. Li et al. / Virology 423 (2012) 30–37were negative for hepatitis B surface antigen, negative for recent acute
infection, and without previous HCV antiviral treatment. Twelve of the
patients were coinfected with HIV while nine were on highly active
antiretroviral therapy (HAART) at the time of study. A written informed
consent was obtained from each subject prior to study participation in
accordance to the regulation of Human Subjects Committee of the Uni-
versity of Washington. Liver biopsies were reviewed by a single study
pathologist (LVT) according to the Batts and Ludwig system with
Inﬂammation Grade (0–4) and Fibrosis Stage (0–4) evaluations (Batts
and Ludwig, 1995). Serum specimens were collected within 30 days of
liver biopsy and stored at −80 °C for further virological analysis. HCV
genotype was determined using restriction fragment length polymor-
phism (RFLP) analysis of sequences ampliﬁed from the 5′ non-coding
region (Davidson et al., 1995), and conﬁrmed by nucleotide sequencing
and phylogenetic analysis (see below). HCV RNA titer was determined
using the third-generation branched DNA assay (VERSANT HCV RNA
3.0, Bayer Diagnostics, Tarrytown, NY), or ultrasensitive real-time
RT-PCR assay.
For in vitro studies, p7 variants were cloned from 3 subjects in the
Harborview cross sectional cohort (one HIV-positive and two HIV-
negative), plus additional 2 viremic subjects from the Alaska Native
cohort (both HIV-negative) (McMahon et al., 2004). Both Alaska Na-
tive persons consented to a long-term hepatitis C study conducted
by the Liver Disease & Hepatitis Program of the Alaska Native Tribal
Health Consortium in Anchorage, AK. This study was approved by
the Alaska Area Institutional Review Board, Native Health boards of
the Alaska Native Tribal Health Consortium, and the Southcentral
Foundation. All 5 subjects were infected with HCV genotype 1a, and
were naïve to HCV treatment. Three subjects developed severe hepa-
titis C disease, as indicated by advanced bridging ﬁbrosis on liver
biopsy (S1, S2 and S3), and two had consistently mild disease (stage 1
ﬁbrosis for subject M1, and stage 0 ﬁbrosis for subject M2).
Cloning and sequence analysis
Total RNA was extracted from the serum samples using the
QIAamp Viral RNA mini kit (Qiagen, Germantown, MD). cDNA was
synthesized from each of the RNA samples using the SuperScript III
One-Step RT-PCR system with Platinum Taq High Fidelity polymerase
and random hexamer primers (Invitrogen, Carlsbad, CA). Nested PCR
was performed afterwards to amplify a 500-bp fragment including
the p7 gene using Platinum Taq High Fidelity polymerase with the
outer primers (sense, 5′-TTGCTCTGCCCCACTGATTG; anti-sense, 5′-CCT-
CCACTTGGTTTTTGTC) and inner primers (sense, 5′-CCTGCTTGTGGAT-
GATGATGTTAC; anti-sense, 5′-GCAAACTGGCTTGAAGAATC). PCR was
initialized at 94 °C for 2 min, followed by 35 cycles of ampliﬁcation at
94 °C for 15 s, 50 °C for 15 s, and 68 °C for 60–90 s and a ﬁnal elongation
at 68 °C for 5 min. The PCR productwas then electrophoresed in agarose
gel with ethidium bromide, followed by gel puriﬁcation of the 500-bp
fragment with the Qiagen Qiaex II Gel Extraction kit (Qiagen, German-
town, MD). The puriﬁed PCR product was then cloned with the ligase-
free TOPO TA Cloning kit (Invitrogen, Carlsbad, CA) and transformed
into competent E. coli cells. Twelve colonies were then picked for each
sample, ampliﬁed with the inner primers of the nested PCR, vacuum
puriﬁed with the Qiagen MinElute 96-well PCR Puriﬁcation kit (Qiagen,
Germantown, MD), and subjected to dye-terminate sequencing.
Expression and puriﬁcation of p7 protein
The selected p7 variants were cloned into expression vectors to
generate bacterial GST–p7 fusion protein as previously described
(Clarke et al., 2006; Grifﬁn et al., 2008). The genes were ampliﬁed
with the PfuTurbo DNA polymerase (Stratagene) and primers incor-
porating EcoRI and NotI sites and an N-terminal FLAG tag (sequences
available on request). Digested amplimers were ligated into the
pGEX-6p-1 vector (GE Healthcare) using T4 DNA ligase (Invitrogen).Resultant GST-FLAGp7 was expressed, cleaved and FLAG-p7 puriﬁed
by reverse phase HPLC as previously described (Clarke et al., 2006).
Liposome dye release assay and pH response test
Channel forming activity of puriﬁed FLAG-p7 proteins was
assessed in a liposome-based ﬂuorescent dye release assay and incor-
porating assays where external reaction buffer pH was altered as pre-
viously described (StGelais et al., 2007).
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